See more : Bharat Bijlee Limited (BBL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of HLB Pharmaceutical Co., Ltd (047920.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HLB Pharmaceutical Co., Ltd, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Lin BioScience, Inc. (6696.TWO) Income Statement Analysis – Financial Results
- Atrion Corporation (ATRI) Income Statement Analysis – Financial Results
- The Goldman Sachs Group, Inc. (GS) Income Statement Analysis – Financial Results
- Shanghai Prosolar Resources Development Co., Ltd (600193.SS) Income Statement Analysis – Financial Results
- McDonald’s Corp (MCDS.NE) Income Statement Analysis – Financial Results
HLB Pharmaceutical Co., Ltd (047920.KQ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.hlbpharma.co.kr
About HLB Pharmaceutical Co., Ltd
HLB Pharmaceutical Co., Ltd, a pharmaceutical company, researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxants, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease. It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services. The company was formerly known as Mediforum Pharmaceutical Incorporation and changed its name to HLB Pharmaceutical Co., Ltd in October 2020. HLB Pharmaceutical Co., Ltd was founded in 1998 and is headquartered in Namyangju-Si, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 135.95B | 107.48B | 62.85B | 40.57B | 36.10B | 20.54B | 15.56B | 20.35B |
| Cost of Revenue | 52.97B | 43.82B | 27.93B | 18.71B | 18.63B | 16.31B | 12.93B | 15.11B |
| Gross Profit | 82.99B | 63.66B | 34.93B | 21.86B | 17.47B | 4.23B | 2.63B | 5.23B |
| Gross Profit Ratio | 61.04% | 59.23% | 55.57% | 53.88% | 48.39% | 20.60% | 16.90% | 25.71% |
| Research & Development | 2.59B | 4.26B | 3.10B | 1.99B | 2.47B | 2.80B | 3.21B | 2.23B |
| General & Administrative | 1.51B | 1.27B | 1.39B | 1.81B | 507.81M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 91.43B | 59.73B | 26.04B | 14.16B | 9.90B | 0.00 | 0.00 | 0.00 |
| SG&A | 98.86B | 65.99B | 31.24B | 18.97B | 13.80B | 7.30B | 3.38B | 2.28B |
| Other Expenses | 1.08B | -356.75M | -347.00M | -254.69M | -197.98M | -246.97M | -197.91M | -117.94M |
| Operating Expenses | 102.53B | 70.60B | 34.69B | 21.21B | 16.46B | 10.34B | 6.78B | 4.63B |
| Cost & Expenses | 155.49B | 114.42B | 62.62B | 39.93B | 35.09B | 26.65B | 19.71B | 19.74B |
| Interest Income | 403.43M | 298.75M | 309.88M | 183.94M | 36.96M | 392.45M | 531.35M | 181.67M |
| Interest Expense | 11.77B | 5.02B | 15.88B | 12.66B | 1.19B | 859.58M | 2.11B | 1.00B |
| Depreciation & Amortization | 5.05B | 4.54B | 3.79B | 2.07B | 1.07B | 1.14B | 1.06B | 797.31M |
| EBITDA | -2.04B | -1.39B | 8.28B | -77.76B | 2.14B | -3.72B | -2.40B | 1.40B |
| EBITDA Ratio | -1.50% | -2.24% | 6.41% | 6.68% | 5.75% | -24.19% | -19.91% | 6.89% |
| Operating Income | -19.54B | -6.94B | 236.89M | 646.10M | 1.01B | -6.11B | -4.15B | 605.41M |
| Operating Income Ratio | -14.37% | -6.46% | 0.38% | 1.59% | 2.79% | -29.75% | -26.70% | 2.98% |
| Total Other Income/Expenses | 3.31B | 655.86M | -13.30B | -93.53B | -1.56B | 108.29M | -1.75B | -723.73M |
| Income Before Tax | -16.23B | -5.78B | -11.39B | -92.48B | -123.03M | -5.72B | -5.56B | -118.33M |
| Income Before Tax Ratio | -11.94% | -5.38% | -18.12% | -227.95% | -0.34% | -27.84% | -35.76% | -0.58% |
| Income Tax Expense | 576.06M | 824.93M | 408.14M | -17.64B | -595.69M | 1.34B | -116.36M | -695.74M |
| Net Income | -19.43B | -11.78B | -13.23B | -74.84B | 472.65M | -7.06B | -5.45B | 577.41M |
| Net Income Ratio | -14.29% | -10.96% | -21.04% | -184.47% | 1.31% | -34.37% | -35.01% | 2.84% |
| EPS | -666.05 | -431.02 | -573.24 | -4.75K | 34.13 | -521.49 | -454.84 | 50.86 |
| EPS Diluted | -666.05 | -431.02 | -573.24 | -4.75K | 34.13 | -521.49 | -454.84 | 50.22 |
| Weighted Avg Shares Out | 29.17M | 27.32M | 23.07M | 15.77M | 13.85M | 13.54M | 11.98M | 11.35M |
| Weighted Avg Shares Out (Dil) | 29.17M | 27.32M | 23.07M | 15.77M | 13.85M | 13.54M | 11.98M | 11.50M |
Source: https://incomestatements.info
Category: Stock Reports